Uptake Dynamics of Cubosome Nanocarriers at Bacterial Surfaces and the Routes for Cargo Internalization
Source abstract
Abstract
Antibiotic-resistant bacteria pose a significant threat to humanity. Gram-negative strains have demonstrated resistance to last resort antibiotics, partially due to their outer membrane, which hinders transport of antimicrobials into the bacterium. Nanocarrier (NC)-mediated drug delivery is one proposed strategy for combating this emerging issue. Here, the uptake of self-assembled lipid nanocarriers of cubic symmetry (cubosomes) into bacteria revealed fundamental differences in the uptake mechanism between Gram-positive and Gram-negative bacteria. For Gram-positive bacteria, the NCs adhere to the outer peptidoglycan layers and slowly internalize to the bacterium. For Gram-negative bacteria, the NCs interact in two stages, fusion with the outer lipid membrane and then diffusion through the inner wall. The self-assembled nature of the cubosomes imparts a unique ability to transfer payloads via membrane fusion. Remarkably, the fusion uptake mechanism allowed rapid NC internalization by the Gram-negative bacteria, overcoming the outer membrane responsible for their heightened resilience. Here this is demonstrated by the marked reduction in the minimal inhibition concentration required for antibiotics against a pathogenic strain of Gram-negative bacteria, Escherichia coli. These results provide mechanistic insight for the development of lipid NCs as a new tool to combat bacteria.
Source: openalex_inverted_index · Quality: baseline
Research context
OpenAlex topics: Bacteriophages and microbial interactions · Antibiotic Resistance in Bacteria · Lipid Membrane Structure and Behavior
SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.
Affiliations
School of Science, STEM College, RMIT University, Melbourne, Victoria 3000, Australia
ARC Centre of Excellence in Convergent Bio-Nano Science and Technology, Department of Chemical Engineering, University of Melbourne, Melbourne, Victoria 3010, Australia
Funding
RMIT University
References (61)
Show source-provided references
1. 2014
2. 10.1016/S1473-3099(13)70318-910.1016/S1473-3099(13)70318-9 ↗
3. 10.1038/nrd397510.1038/nrd3975 ↗
4. 10.1038/nature1704210.1038/nature17042 ↗
5. 2017
6. 10.1038/s41586-019-1665-610.1038/s41586-019-1665-6 ↗
7. 10.1038/s41586-019-1791-110.1038/s41586-019-1791-1 ↗
8. 10.1016/S1473-3099(15)00463-610.1016/S1473-3099(15)00463-6 ↗
9. 10.1016/j.bmc.2016.06.04410.1016/j.bmc.2016.06.044 ↗
10. 10.1016/j.addr.2017.12.01010.1016/j.addr.2017.12.010 ↗
11. 10.1038/nrmicro.2017.9910.1038/nrmicro.2017.99 ↗
12. 10.1016/j.jconrel.2016.01.00810.1016/j.jconrel.2016.01.008 ↗
13. 10.1038/nbt.261410.1038/nbt.2614 ↗
14. 10.1021/acsnano.5b0390210.1021/acsnano.5b03902 ↗
15. 10.2147/IJN.S2659210.2147/IJN.S26592 ↗
16. 10.1021/acs.langmuir.6b0442310.1021/acs.langmuir.6b04423 ↗
17. 10.1021/acsabm.9b0018710.1021/acsabm.9b00187 ↗
18. 10.1016/j.jcis.2020.05.00210.1016/j.jcis.2020.05.002 ↗
19. 10.1021/la802768q10.1021/la802768q ↗
20. 10.1016/j.cis.2014.11.00310.1016/j.cis.2014.11.003 ↗
21. 10.1021/acsnano.8b0796110.1021/acsnano.8b07961 ↗
22. 10.1002/anie.20180406710.1002/anie.201804067 ↗
23. 10.1073/pnas.93.25.1453210.1073/pnas.93.25.14532 ↗
24. 10.1039/c3sm27743g10.1039/c3sm27743g ↗
25. 10.1021/acs.molpharmaceut.8b0089010.1021/acs.molpharmaceut.8b00890 ↗
26. 10.1016/j.colsurfb.2017.01.00410.1016/j.colsurfb.2017.01.004 ↗
27. 10.1016/j.ijpharm.2017.04.08210.1016/j.ijpharm.2017.04.082 ↗
28. 10.1016/j.ejpb.2018.11.00910.1016/j.ejpb.2018.11.009 ↗
29. 10.1016/j.jcis.2020.11.12410.1016/j.jcis.2020.11.124 ↗
30. 10.1002/anie.20120592310.1002/anie.201205923 ↗
31. 10.1016/j.jiec.2011.11.03110.1016/j.jiec.2011.11.031 ↗
32. 10.1021/acsami.9b2178310.1021/acsami.9b21783 ↗
33. 10.1016/j.jcis.2021.02.02710.1016/j.jcis.2021.02.027 ↗
34. 10.1080/1061186029000752210.1080/10611860290007522 ↗
35. 10.2147/IJN.S4261710.2147/IJN.S42617 ↗
36. 10.1021/bi002030k10.1021/bi002030k ↗
37. 10.1016/S0005-2736(99)00217-510.1016/S0005-2736(99)00217-5 ↗
38. 10.1093/jac/41.1.3510.1093/jac/41.1.35 ↗
39. 10.1016/j.ijantimicag.2005.10.02110.1016/j.ijantimicag.2005.10.021 ↗
40. 10.1016/j.ijpharm.2009.11.03310.1016/j.ijpharm.2009.11.033 ↗
41. 10.1128/AAC.01542-0810.1128/AAC.01542-08 ↗
42. 10.1016/j.biomaterials.2010.08.07610.1016/j.biomaterials.2010.08.076 ↗
43. 10.1016/j.jcis.2018.02.04810.1016/j.jcis.2018.02.048 ↗
44. 10.1021/acsbiomaterials.0c0008510.1021/acsbiomaterials.0c00085 ↗
45. 10.1038/s41467-019-12508-810.1038/s41467-019-12508-8 ↗
46. 10.1021/bi301573w10.1021/bi301573w ↗
47. 10.1039/D0RA06120D10.1039/D0RA06120D ↗
48. 10.1021/acsami.9b0182610.1021/acsami.9b01826 ↗
49. 10.1098/rspb.1957.004310.1098/rspb.1957.0043 ↗
50. 10.1016/S0022-5320(67)80084-410.1016/S0022-5320(67)80084-4 ↗
51. 10.1021/ja026085g10.1021/ja026085g ↗
52. 10.1016/j.jconrel.2019.12.03710.1016/j.jconrel.2019.12.037 ↗
53. 10.1002/advs.20180122310.1002/advs.201801223 ↗
54. 10.1016/S1473-3099(01)00091-310.1016/S1473-3099(01)00091-3 ↗
55. 10.1111/jfs.1258110.1111/jfs.12581 ↗
56. 10.1038/srep0921610.1038/srep09216 ↗
57. 10.1016/S0140-6736(98)01267-710.1016/S0140-6736(98)01267-7 ↗
58. 10.1016/j.ijpharm.2015.08.07210.1016/j.ijpharm.2015.08.072 ↗
59. 10.1101/cshperspect.a02543710.1101/cshperspect.a025437 ↗
60. 10.1016/j.ijantimicag.2010.10.00910.1016/j.ijantimicag.2010.10.009 ↗
61. Allan D. · 2016